Company profile: ViraTherapeutics
1.1 - Company Overview
Company description
- Provider of oncolytic virus-based anti-cancer therapeutics, including VSV-GP, a modified Vesicular Stomatitis Virus designed to selectively destroy cancer cells while sparing normal tissues. Offers preclinical safety and efficacy studies for VSV-GP and plans clinical trials to evaluate its therapeutic potential in cancer patients.
Products and services
- Clinical Trials: Patient-based studies in cancer patients that evaluate VSV-GP’s therapeutic potential, assessing anti-cancer effects together with safety and efficacy outcomes
- Modified Vesicular Stomatitis Virus (VSV-GP): Custom-engineered oncolytic immunotherapy product that efficiently destroys cancer cells while sparing normal tissues, delivering highly potent, selective anti-cancer activity
- Preclinical Safety and Efficacy Studies: Preclinical-stage studies evaluating VSV-GP safety profile and effectiveness, generating data required before proceeding to first clinical testing
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ViraTherapeutics
Boston Biomedical
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on novel therapeutics to treat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Boston Biomedical company profile →
Oncogeni
HQ: United Kingdom
Website
- Description: Provider of novel cell- and RNA-based cancer medicines, specializing in small interfering RNA and mesodermal killer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncogeni company profile →
Delphinus Medical
HQ: United States
Website
- Description: Provider of breast cancer screening solutions for hospitals and imaging clinics, developing, commercializing, and servicing the SoftVue 3D Whole Breast Ultrasound Tomography, a 3D whole breast ultrasound system for dense breast screening that increases cancer detection by 20% when used alongside mammography.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delphinus Medical company profile →
Immunome
HQ: United States
Website
- Description: Provider of immunotherapy and antigen discovery solutions, developing targeted therapies including IM-4320 (IL-38-focused tumor control) and 177Lu-FAP radioligand for solid tumors aimed at enhanced tumor radiation delivery. Offers Memory B cell hybridoma technology, a Targeted Effector platform using small-molecule ligands for payload delivery and radioligand design, and the Immunome Discovery Engine to identify novel therapeutic targets and antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunome company profile →
Oncimmune
HQ: United Kingdom
Website
- Description: Provider of proprietary autoantibody assay technologies for early cancer detection, offering ImmunoINSIGHTS analytical platform to discover and profile autoantibody biomarkers for disease characterization, patient stratification, and response prediction; biomarker discovery services; customizable targeted panels and arrays for immuno-oncology and autoimmune diseases; and bioinformatics and data science with multiomics integration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncimmune company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ViraTherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ViraTherapeutics
2.2 - Growth funds investing in similar companies to ViraTherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ViraTherapeutics
4.2 - Public trading comparable groups for ViraTherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →